News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TopoTarget A/S Release: Belinostat Gets EU Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma


10/15/2012 9:45:35 AM

Copenhagen, October 15, 2012 -- On October 15, 2012, the European Commission granted Topotarget A/S an Orphan Drug Designation for belinostat, its novel histone deacetylase (HDAC) inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL). PTCL is a rare form of non-Hodgkin’s lymphoma.

Read at GlobeNewswire

Related News

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES